Loading clinical trials...
Loading clinical trials...
A Clinical Study to Map the HLA GENomic Region and Its potEntial aSsocIation With Selected diSeases in the Greek Population
The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.
The GENESIS study is a multicenter, prospective, non-interventional, clinical study with a target of 12,000 subjects and an anticipated total duration of 36 months. The aim of study GENESIS is to provide a pilot map of HLA genetic variation in the Greek population in order to be used in medical research and for possible clinical applications (evaluation of possible correlations with selected underlying diseases). During the study, each subject will conduct one visit to the participating cite, in which they will provide: 1. Demographic information \[i.e. date of birth, gender, race, ancestry (including information about the subject's grandparents' birthplace), height, weight\], 2. Other information about smoking/vaping, alcohol consumption, arterial blood pressure, diagnosed diseases (if any), current treatments (if any), and 3. Recent (up to 12 months prior to sample collection) results if/when are available from clinical lab tests such as blood count (Hct, Hb, RBC, WBC, PLT count), including a metabolic panel, liver enzymes and biochemical parameters (Glu, HbA1c, TC, TG, LDL-C, HDL-C, ALT, AST, ALP, γGT, bilirubin, LDH, insulin, C-peptide). Upon completion of the data registry, two buccal swabs will be collected per subject and they will be stored at ALTP premises until their shipment to Galatea.Bio. All buccal swab samples will be subjected to genetic material (DNA) extraction. The DNA samples will be further proceeded for HLA genotyping analysis. A follow up analysis will be performed in selected DNA samples via full low-pass whole genome sequencing (LP-WGS), which aims to further investigate the association between the HLA region and autoimmune diseases. Upon completion of the analysis, an individualized ancestry report will be securely made available to all study subjects which they can access, as and if they elect to.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
2nd Propaedeutic Department of Internal Medicine, Attikon University General Hospital
Chaïdári, Attica, Greece
2nd Department of Neurology, AHEPA University Hospital
Thessaloniki, Thessaloniki, Greece
Department of Respiratory Medicine, University General Hospital of Alexandroupolis
Alexandroupoli, Thrace, Greece
Department of Infectious Diseases, 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis
Alexandroupoli, Greece
Department of Cardiology, University General Hospital of Heraklion
Heraklion, Greece
Department of Rheumatology, University Hospital of Heraklion
Heraklion, Greece
Department of Respiratory, University Hospital of Ioannina
Ioannina, Greece
Department of Haematology, University General Hospital of Larissa
Larissa, Greece
Start Date
December 12, 2023
Primary Completion Date
May 31, 2025
Completion Date
August 31, 2026
Last Updated
January 26, 2024
12,000
ESTIMATED participants
Lead Sponsor
Athens LifeTech Park
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00090662